9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Get Help 24/7
logo
Get Help 24/7
mobile logo
Search
 

Archive

25 April
0 Comments
Sticky

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Posted by Goldberg, Persky & White P.C.

Condition Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung Cancer Estimated Enrollment: 24 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MORAb-009-001 Study First Received: May 11, 2006 Last Updated: July 16, 2014 Estimated Primary Completion Date: September 2008 Primary Outcome Measures: Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by Investigator Sponsors and...

Continue reading
25 April
0 Comments
Sticky

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

Posted by Goldberg, Persky & White P.C.

Condition Pleural Neoplasms Estimated Enrollment: 77 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 7216|H3E-US-JMGA Study First Received: July 12, 2004 Last Updated: May 1, 2009 Estimated Primary Completion Date: February 2008 Primary Outcome Measures: Pathological Complete Response|The 1 and 2 Year Disease-Free Survival Rate (Percentage)|Overall Tumor Response|Time to Treatment Failure|Time to Progressive Disease|Overall Survival Time Sponsors and Collaborators: Eli Lilly and Company Result Received: February 16, 2009 Website Link: https://ClinicalTrials.gov/show/NCT00087698...

Continue reading
25 April
0 Comments
Sticky

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Posted by Goldberg, Persky & White P.C.

Condition Esophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000067228|NCI-99-C-0129|NCI-T99-0012 Study First Received: July 11, 2001 Last Updated: April 28, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00019825...

Continue reading
25 April
0 Comments
Sticky

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Posted by Goldberg, Persky & White P.C.

Condition Leukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Primary Peritoneal Cavity Cancer Estimated Enrollment: 22 Age Group: 18 Years to 120 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 06-085|P30CA008748|P01CA023766|MSKCC-06085 Study First Received: November 9, 2006 Last Updated: February 2, 2016 Estimated Primary Completion Date: June 2009 Primary Outcome Measures: Safety|Immune Response Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Innovive Pharmaceuticals Result Received: December 22, 2015 Website Link: https://ClinicalTrials.gov/show/NCT00398138...

Continue reading
25 April
0 Comments
Sticky

Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate

Posted by Goldberg, Persky & White P.C.

Condition Pleural Mesothelioma|Malignant Pleural Mesothelioma Estimated Enrollment: 85 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 03-302 Study First Received: September 12, 2005 Last Updated: March 26, 2014 Estimated Primary Completion Date: July 2006 Primary Outcome Measures: To monitor tumor recurrence and patient survival, and compare those results to historic controls.|To document the morbidity and mortality of this treatment protocol in this patient population|to evaluate the pharmacokinetics of cisplatin. Sponsors and Collaborators: Dana-Farber Cancer Institute|Brigham and Women's Hospital Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00165516...

Continue reading
25 April
0 Comments
Sticky

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Posted by Goldberg, Persky & White P.C.

Condition Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma Estimated Enrollment: 44 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02813|CALGB-30307|CDR0000415372|U10CA031946 Study First Received: April 5, 2005 Last Updated: June 4, 2013 Estimated Primary Completion Date: June 2007 Primary Outcome Measures: Response rate (including complete and partial response)|Time to tumor progression|Percentage of patients remaining failure-free|Overall survival Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00107432...

Continue reading
25 April
0 Comments
Sticky

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Posted by Goldberg, Persky & White P.C.

Condition Malignant Pleural Mesotherioma Estimated Enrollment: 12 Age Group: 20 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 5249|H3E-JE-ME01 Study First Received: November 8, 2005 Last Updated: November 5, 2007 Estimated Primary Completion Date: null Primary Outcome Measures: To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate|Duration of response|Progression free survival|Median survival time|1 year survival rate|Pulmonary function|QOL|Safety|Plasma concentration Sponsors and Collaborators: Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00251550...

Continue reading
25 April
0 Comments
Sticky

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Posted by Goldberg, Persky & White P.C.

Condition Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma Estimated Enrollment: 10 Age Group: 18 Years to 120 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment Study ID Numbers: 100138|10-C-0138 Study First Received: June 11, 2010 Last Updated: April 20, 2017 Estimated Primary Completion Date: February 9, 2015 Primary Outcome Measures: Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients. Sponsors and Collaborators: National...

Continue reading
25 April
0 Comments
Sticky

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Posted by Goldberg, Persky & White P.C.

Condition Carcinoma, Non-Small-Cell Lung|Mesothelioma Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CLBH589B2109 Study First Received: September 26, 2007 Last Updated: November 26, 2012 Estimated Primary Completion Date: January 2009 Primary Outcome Measures: Pharmacokinetic (PK) parameters|Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation Sponsors and Collaborators: Novartis Pharmaceuticals|Novartis Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00535951...

Continue reading
25 April
0 Comments
Sticky

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Posted by Goldberg, Persky & White P.C.

Condition Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer Estimated Enrollment: 27 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: HREC/13/CRGH/199 Study First Received: January 5, 2015 Last Updated: April 5, 2017 Estimated Primary Completion Date: January 4, 2017 Primary Outcome Measures: There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.|to evaluate the effect of multiple dosing of TargomiRs|to detect early signs of efficacy|QOL assessment|ECOG PS change|Pulmonary function change Sponsors and Collaborators: Asbestos Diseases Research Foundation|EnGeneIC Limited Result...

Continue reading